Eli Lilly CEO David Ricks Meets Union Minister to Strengthen Ties in Insulin & NCD Therapies

The talks also covered the establishment of a Centre of Excellence for insulin therapies, as well as clinical trials for advanced treatment options

Global CEO of Eli Lilly, world’s pioneer Insulin manufacturing Company, David Ricks called on Union Minister of State (Independent Charge) for Science and Technology; Earth Sciences and Minister of State for PMO, Department of Atomic Energy, Department of Space, Personnel, Public Grievances and Pensions, Dr. Jitendra Singh to discuss strengthening partnership, with a focus on Insulin and Non-Communicable Disease (NCD) therapies as well as biomanufacturing.

Eli Lilly, a global pharmaceutical giant headquartered in Indianapolis, Indiana and a global pioneer in Insulin production for Diabetes and several other drugs particularly for Cancer etc has a significant presence in India through its subsidiary, Eli Lilly and Company (India) Pvt. Ltd. The company imports and markets medicines for diabetes, gastric cancer, lung cancer, breast cancer, osteoporosis, rheumatoid arthritis, and other critical diseases. Its operations also extend to Nepal, Bangladesh, and Sri Lanka through partnerships with local pharmaceutical firms.

The talks also covered the establishment of a Centre of Excellence for insulin therapies, as well as clinical trials for advanced treatment options.

Dr. Jitendra Singh, himself a renowned Endocrinologist, emphasized on carrying out studies particularly for India, as there is difference in metabolic disorders faced in India and the rest part of the world. He stressed that food habits and phenotype are different thus central obesity and visceral obesity is quite prevalent.

With diabetes being a major health concern in India, discussions on expanding insulin production and accessibility hold immense significance. Dr. Jitendra Singh, who has been vocal about leveraging biotechnology for affordable healthcare solutions, welcomed the dialogue, emphasizing India’s growing capabilities in pharmaceuticals and clinical research. The conversation aligns with the government’s broader push for self-reliance in drug manufacturing and innovation in life sciences.

Referring to India’s push for affordable healthcare for all and the importance of generic medicine, Dr. Jitendra Singh said “Both Generic Medicine and advancement in specialized medicine can co-exist in India.

Eli Lilly’s engagement aligns with the government’s broader vision of achieving self-reliance in drug manufacturing and advancing innovation in life sciences. Dr. Jitendra Singh has emphasized that bio-manufacturing plays a crucial role in India’s Atmanirbhar Bharat initiative by reducing import dependence and ensuring wider access to cutting-edge therapies. He has pointed out that India’s robust pharmaceutical industry, evolving biotech ecosystem, and highly skilled scientific workforce position the country as a potential global leader in bio-manufacturing. The Minister has also highlighted the importance of government-industry collaboration in accelerating research, streamlining regulatory processes, and driving innovation, particularly in insulin production and treatments for non-communicable diseases.

Eli Lilly’s engagement with India comes at a time when the country is focusing on bolstering its pharmaceutical industry, not just for domestic needs but also as a global supplier. The potential establishment of a Centre of Excellence could serve as a critical step in making insulin therapies more accessible, reinforcing India’s role in combating lifestyle diseases.

The meeting underscores the increasing collaboration between global pharmaceutical firms and the Indian government, with a shared vision of enhancing healthcare accessibility and advancing research in non-communicable diseases.